Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.
Michel Bila(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Amelie Franken(VIB-KU Leuven Center for Cancer Biology), Sabine Tejpar(KU Leuven), Cedric Van Aerde(Universitair Ziekenhuis Leuven), Karolien Goffin(KU Leuven), Esther Hauben(Universitair Ziekenhuis Leuven), Valentina Pomella(Universitair Ziekenhuis Leuven), Jeroen Van Dessel(Universitair Ziekenhuis Leuven), Sara Verbandt(Universitair Ziekenhuis Leuven), Vincent Vander Poorten(KU Leuven), Vincent Vandecaveye(KU Leuven), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Thomas Van Brussel(VIB-KU Leuven Center for Cancer Biology), Sigrid Hatse(Rega Institute for Medical Research), Rogier Schepers(VIB-KU Leuven Center for Cancer Biology)
Cited by 2
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants
|JNCI Journal of the National Cancer Institute|2015|570